Kornitzer Capital Management Inc. KS Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Kornitzer Capital Management opened a new position in Regeneron, buying 1,891 shares in Q4—about $1.46 million worth of stock.
• Q1 beat and shareholder actions: Regeneron reported EPS of $9.47 (vs. $8.91 est.) and revenue of $3.61B (+19% YoY), and announced a $3 billion share buyback while declaring a $0.94 quarterly dividend (≈0.5% yield).
• Mixed market reaction and positioning: Analysts are split—some raised targets (Guggenheim to $995, Evercore to $875) while others trimmed forecasts; institutional ownership is high at 83.31% and insiders have recently reduced holdings.

Kornitzer Capital Management Inc. KS acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,891 shares of the biopharmaceutical company's stock, valued at approximately $1,460,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. raised its holdings in shares of Regeneron Pharmaceuticals by 153.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company's stock valued at $67,969,000 after purchasing an additional 73,176 shares in the last quarter. PGGM Investments raised its holdings in shares of Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company's stock valued at $52,057,000 after purchasing an additional 8,187 shares in the last quarter. Sound Shore Management Inc CT bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $64,677,000. Rakuten Investment Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $33,121,000. Finally, Ellerson Group Inc. ADV raised its holdings in shares of Regeneron Pharmaceuticals by 49.2% in the 3rd quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company's stock valued at $4,556,000 after purchasing an additional 2,671 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $701.42 on Monday. The company has a market cap of $74.15 billion, a PE ratio of 17.09, a P/E/G ratio of 1.60 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company's 50 day moving average is $756.81 and its two-hundred day moving average is $737.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals's revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.22 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.05 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director owned 17,803 shares of the company's stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,774 shares of company stock valued at $2,942,738. Insiders own 7.02% of the company's stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Analyst Upgrades and Downgrades

Several research firms have recently commented on REGN. Evercore boosted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an "outperform" rating in a report on Thursday, January 22nd. Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating for the company in a report on Thursday. Zacks Research lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, February 6th. Finally, Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $826.59.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.